PANews on March 21 reported that YZi Labs posted on the X platform to announce that Jane He has been appointed as its general partner, leading biotech investments and contributing to the company's broad strategy in AI and Web3.

Prior to joining YZi Labs, Jane served as an investor and chief operating officer at a Hong Kong-based hedge fund, focusing on growth investments in the biotech and innovation-driven sectors. Her investment portfolio and research cover cancer therapies (immunotherapy, cell therapy, antibody-drug conjugates), metabolic therapies (GLP-1 drugs for obesity and type 2 diabetes), oligonucleotide therapies (mRNA, siRNA, ASO), gene editing, sequencing, and medical devices. She also actively explores opportunities at the intersection of AI and biotech. Jane previously held leadership roles at the alternative investment management firm PAAMCO Prisma, overseeing its investments in other funds across Asia. Jane holds an MBA from Stanford University, graduating as an Arjay Miller Scholar.